What is the long-term trend for Ultragenyx Pharmaceutical's other commercial liabilities?

Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's other commercial liabilities has grown at a 19.6% compound annual growth rate (CAGR), from $108.49M to $265M.

Ultragenyx Pharmaceutical RARE Other Commercial Liabilities

Other Commercial Liabilities at other companies

AmgenAMGN

——

Ionis PharmaceuticalsIONS

——

Arrowhead ResearchARWR

——

CRISPR TherapeuticsCRSP

——

ModernaMRNA

——

Denali Therapeutics Inc.DNLI

——

Other financials

Income statement

See full

Revenue$136.0M-2.2%

Operating income-$169.0M-18.2%

Net income-$185.0M-22.5%

EPS (diluted)-$1.84-17.2%

Balance sheet

See full

Cash & equivalents$175.0M+37.8%

Total debt$36.0M-10.8%

Total equity-$236.0M-264%

Total assets$1.3B-1.2%

Cash flow

See full

Operating cash flow-$197.0M-18.7%

CapEx$1.0M0.0%

Free cash flow-$198.0M-18.6%

Valuation

See full

Market cap$2.83B-39.4%

P/S4.2×-3.7×

Profitability

See full

Gross margin97.2%—

Operating margin-83.8%-3.0pp

Net margin-90.9%-2.1pp

FCF margin-75.1%+10.7pp

Returns & leverage

See full

Return on equity-325.6%+36.9pp

Debt / equity3.7×—

Current ratio2×-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's other commercial liabilities?: Ultragenyx Pharmaceutical (RARE) reported other commercial liabilities of $194M in Q1 2026.
How has Ultragenyx Pharmaceutical's other commercial liabilities changed year-over-year?: Ultragenyx Pharmaceutical's other commercial liabilities increased by 12.1% year-over-year, from $173.01M to $194M.
What is the long-term trend for Ultragenyx Pharmaceutical's other commercial liabilities?: Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's other commercial liabilities has grown at a 19.6% compound annual growth rate (CAGR), from $108.49M to $265M.